COMMUNIQUÉS West-GlobeNewswire

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
23/10/2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s ( [...]
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close [...]
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
23/10/2025
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development [...]
PCI Biotech update
23/10/2025
Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations. Reference is made to the company’s announcements dated 18 th August 2025 and 25 th September [...]
Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
23/10/2025
-- First-in-class non-oncolytic arenavirus-based approach designed to induce targeted, effective, and durable anti-cancer activity against primary tumors and metastases – -- Phase 1 study to evaluate the safety and [...]
Hydreight Reports Corporate Update and Ranks #25 on Deloitte’s 2025 Technology Fast 50™
23/10/2025
Over 295,000 VSDHOne product orders between July and September, accelerating nurse network growth and a strong balance sheet with approximately CA$18.7 million in cash; Hydreight continues to build the infrastructure [...]
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
23/10/2025
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and [...]
'The World’s Greatest Health Van' Travels to Ottawa: 150,000 Canadians Call for The Charter of Health Freedom
23/10/2025
OTTAWA, Ontario, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Shawn Buckley, President of the Natural Health Product Protection Association (NHPPA), is on the road — destination Parliament Hill, Ottawa. His main purpose is to [...]
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
23/10/2025
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
23/10/2025
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today welcomes updated guidelines from the Society of Nuclear Medicine and [...]
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
23/10/2025
– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR [...]
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
23/10/2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to [...]
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company [...]
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
23/10/2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical- [...]
Redhook Brewing Launches Redhook 81, Celebrating Pacific Northwest Roots and the Spirit of Hard Work
23/10/2025
Redhook 81, a Cold One for Quittin’ Time SEATTLE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Redhook Brewing , creator of the hardest working beer in the fridge and a craft brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: [...]
Conavi Medical to Highlight Novasight Hybrid™ Imaging at TCT 2025
23/10/2025
Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technology TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a commercial-stage [...]
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
23/10/2025
Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its ambition to bring [...]
TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate
23/10/2025
GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placebo Trial results were presented during a plenary session of the World Stroke Congress 2025 in Barcelona London, UK [...]
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6 th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP [...]

Pages